Company Profile

C2N Diagnostics LLC
Profile last edited on: 4/12/23      CAGE: 56YP1      UEI: TE1NNNXJQCD7

Business Identifier: Novel diagnostics and therapies for Alzheimer’s diseas
Year Founded
2007
First Award
2009
Latest Award
2020
Program Status
Active
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

4340 Duncan Avenue
Saint Louis, MO 63110
   (877) 226-3424
   info@c2ndiagnostics.com
   www.c2ndiagnostics.com
Location: Single
Congr. District: 01
County: St. Louis city

Public Profile

Based on technology developed within the neuroscience laboratories of Washington University School of Medicine, Saint Louis, MO, LifeTech Research, Inc. of Baltimore MD co-founded C2N Diagnostics. The firm is usefully understood as a specialty diagnostics company structured around accelerating novel diagnostics and therapies for Alzheimer's disease. The company offers precise, accurate, and sensitive mass spectrometry-based identification, quantification, and monitoring of proteins, protein fragments, and other biomolecules implicated in human neurological diseases, enabling doctors to detect and characterize neurocognitive disorders. The vision of C?N Diagnostics personnel is to bring Clarity Through Innovation™. The firm focuses its therapeutic discovery efforts around mechanism-based approaches to prevent or stop the progression of human neurological disorders. Diagnostic efforts revolve around bringing accurate, widely accessible, and cost-effective blood tests to the clinic for the betterment of patient care and brain health monitoring. Its lead commercial product -- the PrecivityAD™ blood test -- is a mass spectrometry-based test performed in C?N’s CLIA-certified lab that measures in blood multiple analytes including A?42, A?40, and apolipoprotein E isoforms. While the test by itself cannot diagnose Alzheimer’s disease — which is a clinical diagnosis made by a health care provider — the test is an important new tool for physicians to aid in the ev

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
25-49
Revenue Range
2.5M-5M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
5-9

Awards Distribution by Agency

Key People / Management

  Joel B Braunstein -- Co-Founder, President and CEO

  Randall Bateman

  John Contois -- Vice President, Laboratory Medicine

  Patricia Desimone -- Assistant General Counsel & Vice President of Human Resources

  David Holtzman

  Micah Onixt -- General Counsel, Privacy Officer and Corporate Secretary

  Tim Veenstra -- Senior VP of Diagnostic Sciences and Innovation

  Philip Verghese -- Vice President, Translational Sciences and Operations

  Tim West -- VP of Research and Development

  Kevin Yarasheski -- Senior Vice President